Literature DB >> 9920013

Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

K M Uramoto1, C J Michet, J Thumboo, J Sunku, W M O'Fallon, S E Gabriel.   

Abstract

OBJECTIVE: To describe trends in systemic lupus erythematosus (SLE) incidence and mortality over the past 4 decades.
METHODS: Using the Rochester Epidemiology Project resources, medical records were screened to identify all Rochester, Minnesota residents with any SLE-associated diagnoses, discoid lupus, positivity for antinuclear antibodies, and/or false-positive syphilis test results determined between January 1, 1980 and December 31, 1992. Medical records were then reviewed using a pretested data collection form in order to identify cases of SLE according to the American College of Rheumatology 1982 revised criteria for SLE. Drug-induced cases were excluded. All identified SLE patients were followed up until death, migration from the county, or October 1, 1997. These data were combined with similar data from the same community obtained between 1950 and 1979, and trends in the SLE incidence and mortality over time were calculated.
RESULTS: Of the 430 medical records reviewed, 48 newly diagnosed cases of SLE (42 women and 6 men) were identified between 1980 and 1992. The average incidence rate (age- and sex-adjusted to the 1970 US white population) was 5.56 per 100,000 (95% confidence interval [95% CI] 3.93-7.19), compared with an incidence of 1.51 (95% CI 0.85-2.17) in the 1950-1979 cohort. The age- and sex-adjusted prevalence rate as of January 1, 1993 was approximately 1.22 per 1,000 (95% CI 0.97-1.47). Survival among SLE patients was significantly worse than in the general population (P = 0.017 compared with the 1980-1992 cohort, and P < 0.0001 compared with the 1950-1979 cohort, by log-rank test). Cox proportional hazards modeling demonstrated a statistically significant improvement in the survival rate over time (P = 0.035).
CONCLUSION: Over the past 4 decades, the incidence of SLE has nearly tripled, and there has been a statistically significant improvement in survival. These findings are likely due to a combination of improved recognition of mild disease and better approaches to therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920013     DOI: 10.1002/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  106 in total

1.  Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States.

Authors:  Sudumpai Jarukitsopa; Deana D Hoganson; Cynthia S Crowson; Olayemi Sokumbi; Mark D Davis; Clement J Michet; Eric L Matteson; Hilal Maradit Kremers; Vaidehi R Chowdhary
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

Review 2.  Nasal manifestations of systemic illnesses.

Authors:  Isam Alobid; Jose Maria Guilemany; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

3.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

4.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

5.  Prevalence and incidence of systemic lupus erythematosus in South Korea.

Authors:  Jee-Seon Shim; Yoon-Kyoung Sung; Young Bin Joo; Hye-Soon Lee; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

6.  Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.

Authors:  Maria I Danila; Guillermo J Pons-Estel; Jie Zhang; Luis M Vilá; John D Reveille; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-02-20       Impact factor: 7.580

7.  EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.

Authors:  C-S Yee; C Gordon; C Dostal; P Petera; J Dadoniene; B Griffiths; B Rozman; D A Isenberg; G Sturfelt; O Nived; J H Turney; A Venalis; D Adu; J S Smolen; P Emery
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

8.  Levels of serum procalcitonin and C-reactive protein for evaluating pulmonary bacterial infection in patients with lupus erythematosus.

Authors:  Jing Gao; Lei Zhang; Xin Zhang; Shi-Long Zhao; Sheng-Yun Liu; Li-Hua Xing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 9.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Epidemiology of systemic lupus erythematosus: capturing the butterfly.

Authors:  S Sam Lim; Cristina Drenkard
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.